. Characteristics of the studies included in the systematic review and meta-analysis. Randomised phase II trial of panitumumab, erlotinib, and gemcitabine versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma. Panitumumab 4 mg/kg every two weeks, Erlotinib 100 mg daily, Gemcitabine 1000 mg/m 2 weekly on a 28-day cycle. Capecitabine plus Erlotinib in Gemcitabine-refractory advanced pancreatic cancer. Capecitabine1000 mg/m 2 twice daily for 2 weeks, followed by a 1-week break + Erlotinib 150 mg daily. Kullmann et al. 2009 [39,40] Phase 2 62 64.5 0-3 LA = 0 M = 32 1st 61
Study
Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Cetuximab 400 mg/m 2 at first infusion followed by weekly 250 mg/m 2 combined with Gem 1000 mg/m 2 as a 100-min infusion on day 1 and Oxaliplatin 100 mg/m 2 as a 2-h infusion on day 2 every 2 weeks. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with Gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. Cetuximab at an initial dose of 400 mg/m 2 , followed by 250 mg/m 2 weekly for 7 weeks. Gemcitabine was administered at 1000 mg/m 2 for 7 weeks, followed by 1 week of rest. In subsequent cycles, Cetuximab was administered weekly, and Gemcitabine was administered weekly for 3 weeks every 4 weeks.
